Eli Lilly ordered to pay $176.5 million to Teva in U.S. migraine drug patent trial
Eli Lilly (NYSE:LLY) Loses Migraine Drug Patent Trial to Teva
Teva's migraine drug Ajovy looks set for EU approval -
Xconomy: Teva Wins FDA Nod for Migraine Drug, Sets Price in Line with Amgen's
Teva's Migraine Treatment Effective In Patients With Co-Morbid Depression
With clock ticking on Teva migraine drug, analyst expresses doubt for approval | Fierce Pharma
Teva Shares Pop as FDA Approves Its Migraine Drug - TheStreet
Teva stops selling migraine patch after reports of burns
AbbVie, Biohaven, Teva and Satsuma tackle migraine at AHS – PharmaLive
Teva's recalled migraine medicine Zecuity has a long local history - Philadelphia Business Journal
Teva Canada Announces Product Availability of AJOVY™ | Business Wire
FDA approves Teva's migraine injection AJOVY™ - Pf Media
Teva Canada Announces New Autoinjector for AJOVY® for the Preventive Treatment of Migraine in Adults | Business Wire
No joy for Ajovy: Teva's migraine drug can't find a convincing win in meta-analysis versus Biohaven, AbbVie meds | Fierce Pharma
Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed - Ypsomed - Sverige
Teva Analysts Say Migraine Drug Approval Gives Needed Relief - Bloomberg
Teva's migraine med given marketing authorization
Teva Pharmaceuticals on Twitter: "Meet our #migraine expert, Dr Joshua Cohen, as he shares his own story of living with #migraine and explains the impact the disease can have on patients. Read
U.S. Health Regulator Approves Teva's Migraine Drug
Ajovy Now Available in Autoinjector Device for Migraine Prevention - MPR
Teva to suspend sales of Zecuity migraine patch
Preventive Treatment of Migraine–AJOVY® (fremanezumab-vfrm) injection
Beyond Migraine
Teva Wins Three, Loses Six in Patent Battle Over Migraine Drug – PharmaLive
